Grassley Direct

I spoke with AJ Taylor of KIOW Radio and Mike Hohenbrink of the Calmar Courier about the death tax, the Supreme Court vacancy, the repeal and replacement of Obamacare, NAFTA and TPP, the Keystone XL and Dakota Access pipelines and President Trump's executive orders.

Q&A: Balanced Budget Amendment

Q. Why are you co-sponsoring an amendment requiring Congress to pass a balanced budget?
Q. What is the fiscal outlook for the federal government?
Q. How would your Balanced Budget Amendment work?

Quick Links

On Tuesday I went to the White House for a meeting with President Trump, Vice President Pence, Leader McConnell, Minority Leader Schumer and Ranking Member Feinstein about the Supreme Court vacancy. Throughout the past year, I said that no matter who won the election, we would move the process forward with the new President's nominee. In the meeting, I told the President that he made a very good start with his list of 21 widely respected and mainstream judges. I recorded a few more of my thoughts in the following video.

It's getting harder all the time to have a family farm or a family-run business, and Congress ought to do everything possible to encourage family enterprises to stay in operation and get next generations involved. I'm cosponsoring legislation that was reintroduced this week to permanently repeal the federal estate tax, more commonly known as the death tax. The estate tax is counter-productive to jobs, economic growth and the promotion of family enterprises.

I've reintroduced legislation to aid businesses in complying with immigration laws by certifying the legal status of their workforce. The bill would permanently authorize and require employers to use the E-Verfiy program, an internet-based system that assists employers in determining whether an employee can legally work in the United States. There is also no cost for using the E-Verify system.

I had to write to the Centers for Medicare and Medicaid Services (CMS) a second time to request answers on whether it has taken any action to recover taxpayer dollars used to pay for misclassified EpiPens. I received a lackluster and very disappointing response to my previous letter. It provided no details about any specific action the agency took and attempted to dodge responsibility for a problem that likely cost the taxpayers hundreds of millions of dollars.

Post of the Week